Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor

Oct 14, 2006American journal of physiology. Regulatory, integrative and comparative physiology

Oxyntomodulin raises natural heart rate in mice without involving the glucagon-like peptide-1 receptor

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Peripherally administered Oxyntomodulin (OXM) significantly increased heart rate by >200 beats/min, reaching a maximum of 728 ± 11 beats/min in wild-type mice.

  • OXM elevates intrinsic heart rate in mice, independent of the sympathetic nervous system.
  • The increase in heart rate is observed in both wild-type and Glp-1R(-/-) mice, suggesting a GLP-1 receptor-independent mechanism.
  • OXM also inhibits food intake and reduces activity levels in wild-type mice, effects that are dependent on the GLP-1 receptor.
  • Body temperature is lowered by OXM in autonomically blocked mice, indicating additional physiological effects.

AI simplified

Full Text

Full text is available at the source.
View full text ↗

Related papers

Aug '04
Oxyntomodulin and GLP-1 differently affect eating and energy use in mice
top 1% journal
cited by 317 papers
research support, non-u.s. gov't
Aug '08
Oxyntomodulin improves insulin-producing cell function but does not slow stomach emptying in mice
cited by 95 papers
research support, non-u.s. gov't
Feb '10
Effects of GLP-1 and oxyntomodulin on hunger-sensitive brain cells in the hypothalamus
cited by 24 papers
research support, non-u.s. gov't
Mar '04
Oxyntomodulin from outside the brain lowers eating and weight gain in rats
cited by 271 papers
research support, non-u.s. gov't
Jan '23
Discovery of new drugs that activate both blood sugar control and appetite regulation receptors
cited by 2 papers
research support, non-u.s. gov't
Dec '20
New peptide activating two hormone receptors reduces diabetes and its complications when combined with gentle ultrasound
research support, non-u.s. gov't

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
3 days ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
1 week ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
2 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
3 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
4 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
5 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
6 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
7 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
8 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief